AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Date of Call: October 30, 2025
10.8% year-over-year increase in revenue to $185.9 million in Q3 2025. - This growth was driven by broad-based demand across practices and regions, with 7 out of 11 practices growing year-over-year.30.3% year-over-year, contributing significantly to the overall revenue growth.Growth was primarily attributed to strong performance in the Antitrust & Competition Economics and Life Sciences practices.
Legal and Regulatory Services Expansion:
11.5%, supported by ongoing merger-related activity and demand for antitrust services.The growth was driven by high-profile mergers and regulatory reviews, such as the U.S. Department of Justice's review of the UnitedHealth-Amedisys acquisition.
Utilization and Profitability:
77%, which exceeded revenue growth, indicating strong operational efficiency.Non-GAAP net income, earnings per diluted share, and EBITDA all increased by 12.7%, 16.4%, and 14.6%, respectively, reflecting strong profitability.
Capital Deployment and Shareholder Returns:
$7.2 million to shareholders through dividends and share repurchases in Q3 2025.16%, demonstrating confidence in its business performance.Overall Tone: Positive
Contradiction Point 1
Headcount and Growth Strategy
It involves the company's headcount strategy and growth expectations, which are crucial for understanding the company's future performance and resource allocation.
Regarding headcount, why wasn't there a larger increase in junior consultants quarter-over-quarter, considering seasonal factors? - Andrew Nicholas (William Blair & Company L.L.C., Research Division)
2025Q3: The headcount volatility or changes that you've seen, say, in the last 12 to 24 months are really us evaluating these growth opportunities at times where we think the potential is not there for future growth. We redeploy the assets to somewhere else in the firm. - Paul Maleh(CEO)
Will new college graduates join typical, larger, or smaller classes? - Andrew Nicholas (William Blair & Company L.L.C., Research Division)
2025Q2: We're investing in practices with growth potential, redeploying investments as needed. - Paul Maleh(CEO)
Contradiction Point 2
Rate Increases and Billing Rates
It involves the company's billing rates and rate increase strategy, which directly impacts revenue and pricing expectations.
Are the low double-digit aggregate bill rate increases driven by rate hikes, mix, or other factors? - Andrew Nicholas (William Blair & Company L.L.C., Research Division)
2025Q3: Our rate increases are set usually towards the end of the preceding year and go into the beginning of the current year. So rate increases happens the majority of it during Q1 of fiscal 2025. As new projects come online, we get to realize more of the full benefit of that rate increase. I believe in 2025, I think the effective rate increase is right around 3%, give or take. - Paul Maleh(CEO)
How is the pricing environment, and have there been any pushbacks? - Marc Riddick (Sidoti & Company, LLC)
2025Q2: Rate increases for fiscal 2025 have been realized. - Paul Maleh(CEO)
Contradiction Point 3
International Growth Strategy
It involves the company's international growth strategy, which is vital for understanding the company's geographic expansion and revenue diversification.
Are certain client verticals more active in specific areas of the business? - Marc Riddick (Sidoti & Company, LLC)
2025Q3: The consistency of the strong enforcement in comparing that to North America. But it starts with just the amazing quality of the group we have over there in Europe. - Paul Maleh(CEO)
What are the key drivers of the guidance increase and what is the current visibility level? - Marc Riddick (Sidoti & Company, LLC)
2025Q2: Strong first half of fiscal 2025 continued from the strong performance in fiscal 2024. The level of lead flow activity has been positive. - Paul Maleh(CEO)
Contradiction Point 4
Headcount Growth and Sustainability
It involves differing explanations regarding the sustainability of the headcount ratio between junior and senior consultants, which could have implications for future growth and operational efficiency.
Why wasn’t there a larger quarter-over-quarter increase in junior consultant headcount, given the seasonal dynamics? - Andrew Nicholas (William Blair & Company L.L.C., Research Division)
2025Q3: The headcount volatility or changes that you've seen, say, in the last 12 to 24 months are really us evaluating these growth opportunities at times where we think the potential is not there for future growth. We redeploy the assets to somewhere else in the firm. - Paul Maleh(CEO)
Can you clarify the headcount numbers, specifically the increase from 5,700 to 6,000 over the past 12 months, and whether the 5,700 figure was capitalized or an estimate? - James Friedman (Jefferies)
2025Q1: We are at the stage where we are beginning to see that the investment in headcount that we made in 2024 is now starting to bear fruit. - Paul Maleh(CEO)
Contradiction Point 5
Regulatory Scrutiny and Antitrust Enforcement
It reflects potential changes in regulatory scrutiny and enforcement, which could impact the company's business and client base.
2025Q3: The Antitrust & Competition Economics practice is delivering record quarter after record quarter. - Paul Maleh(CEO)
How are different practices contributing to the 2025 outlook? - Kevin Steinke (Barrington Research)
2024Q4: There's a shift. Areas that were quiet are now beginning to see healthy activity. But I want to point out again, we are anticipating a more balanced growth model. - Paul Maleh(CEO)
Discover what executives don't want to reveal in conference calls

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet